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Objective: Vascular endothelial growth factor (VEGFA) and its receptor VEGFR2 
drive angiogenesis in a number of pathologies, including diabetic retinopathy, wet 
age-related macular degeneration and cancer. Studies suggest roles for heparan 
sulfate proteoglycans (HSPG) in this process although the nature of this involvement 
remains elusive. Here, we set to establish the role of the HSPG Syndecan-4 (SDC4) 
in pathological angiogenesis. 
Approach and Results: We report that angiogenesis is impaired in mice null for 
SDC4 in models of neovascular eye disease and tumor development. Our work 
demonstrates that SDC4 is the only syndecan whose gene expression is 
upregulated during pathological angiogenesis and is selectively enriched on 
immature vessels in retinas from diabetic retinopathy patients. Combining in vivo and 
tissue culture models, we identified SDC4 as a downstream mediator of functional 
angiogenic responses to VEGFA. We found that SDC4 resides at endothelial cell 
(EC) junctions, interacts with VE-Cadherin and is required for its internalization in 
response to VEGFA. Finally, we show that pathological angiogenic responses are 
inhibited in a model of wet age-related macular degeneration by targeting SDC4. 
Conclusions: We show that SDC4 is a downstream mediator of VEGFA-induced 
VE-Cadherin internalization during pathological angiogenesis and a potential target 
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Angiogenesis is a critical developmental process and an essential component of 
physiological tissue regeneration 1. In the pathogenesis of neovascular eye 
diseases, cancer and inflammatory disorders, new blood vessel formation is a key 
feature and significant efforts have been made to control this process for therapeutic 
benefit 2-6. The pro-angiogenic cytokine vascular endothelial growth factor A 
(VEGFA) and its receptor VEGFR2 regulate angiogenesis in these pathologies; 
promoting endothelial cell (EC) survival, proliferation and migration 7. The movement 
of ECs during new vessel growth depends on the remodeling of EC junctions and 
VEGFA has a crucial role in regulating the junctional concentration of vascular 
endothelial cadherin (VE-Cadherin) 8-12. The presence of a heparin binding domain 
on the most biologically active isoform of VEGFA, VEGFA164/165, is suggestive of a 
role for heparan sulfate proteoglycans (HSPGs) in angiogenesis, particularly in 
facilitating the engagement of ligand with receptor 13, 14. For this reason the four-
member syndecan family of HSPGs have been proposed to have roles in this 
process 15. Syndecans consist of a short cytoplasmic domain, a single-pass 
transmembrane domain and a larger extracellular core protein which is substituted 
with predominantly HS chains. Numerous interactions with these sugars and 
bioactive molecules such as growth factors and extracellular matrix molecules have 
been reported 16-19. Recent studies have shown syndecan-2 (SDC2) forms a tri-
molecular complex with VEGFA165 and VEGFR2 leading to enhanced signaling. In 
contrast, syndecan-4 (SDC4), the family member most closely related to SDC2, has 
no impact on VEGFA signaling. This difference was linked to enhanced 6-O-sulfation 
on SDC2 HS chains which is determined by unique sequence motifs contained in the 
extracellular core protein of SDC2 20. Several studies have identified a pro-
angiogenic role for SDC4 in response to stimuli such as FGF2 and Prostaglandin E2 
and adult Sdc4-/- mice exhibit defects in the development of fetal vessels in the 
placental labyrinth and in angiogenesis during granulation tissue formation after 
wounding 21-25. All of which, is suggestive of a functional requirement for SDC4 in 
new blood vessel formation.  
Here, we set out to elucidate the function of SDC4 in VEGFA-driven pathological 
angiogenesis using a variety of disease models. We found that Sdc4-/- animals are 
protected in both murine models of neovascular eye disease and skin tumor models. 
SDC4 gene expression, unlike that of other family members, increases during 
pathological angiogenesis but not during developmental angiogenesis in mice, and is 
selectively expressed on immature blood vessels in retinas of diabetic retinopathy 
patients. Functional assays, such as VEGFA-induced ex vivo sprouting and cell 
migration demonstrate a strong requirement for SDC4, although VEGFR2 signaling 
in response to VEGFA is normal in Sdc4-/- null ECs. We show that SDC4 acts 
downstream of VEGFA/VEGFR2, and is required for efficient VE-Cadherin trafficking 
away from EC junctions in response to VEGFA. Finally, we demonstrate that 
targeting SDC4/VE Cadherin interaction in a pre-clinical model of Wet Age-Related 
Macular Degeneration leads to inhibition of pathological angiogenesis. These 
findings identify SDC4 as an important regulator of VE-Cadherin trafficking in 
VEGFA-driven junctional reorganization, an essential component of pathological 
angiogenesis, and as such has the potential to be targeted for therapeutic benefit. 
  




MATERIALS AND METHODS 
 
Please see the Major Resources Table and additional Materials and Methods in 
the Supplemental Material. 
Experimental animals: Sdc4-/- mice (on a C57BL/6J background)22 were obtained 
from the Centre for Animal Resources and Development (CARD, Kunamoto 
University, Japan) with the kind permission of Professor Tetsuhito Kojima (Nagoya 
University, Japan). All adult mice were used at an age between 5-8 weeks at an 
average weight of 25 g. Unless stated male mice were used since sex differences in 
the responses measured are negligible. As appropriate, age-matched control mice 
were littermates or C57BL/6J wild-type mice purchased from Charles River. Unless 
stated male animals were used in these studies, since the differences between 
males and females in the models used is negligible. Animals were housed and 
treated in Accordance with UK Home Office Regulations and all experiments were 
approved by the UK Home Office according to the Animals Scientific Procedures Act 
1986 (ASPA) and by the National Animal Ethics Committee of Finland. 
Developmental angiogenesis mouse model: Neonatal WT, Sdc4+/- and Sdc4-/- 
littermates (both male and female) were euthanized at P6 and retinal flat mounts 
were prepared for lectin GS-II staining. Briefly, retinas were washed extensively in 
PBS, blocked in 3% BSA followed by overnight staining with lectin GS-II-Alexa594 
and an anti-αSMA-alexa488 antibody (1:150, Sigma, in-house conjugated) in 0.5% 
triton in PBS. Retinas were imaged using confocal microscopy (Carl Zeiss LSM 700) 
with 10× objective. The rate of developmental angiogenesis at P6 was determined by 
measuring the diameter of vasculature via the optic nerve to the tips of the blood 
vessels. Two measurements per retina were taken and an average was calculated. 
Oxygen-induced retinopathy (OIR) mouse model: Neonatal mice (both male and 
female) at P7 were exposed to 75% oxygen for 5 days with their nursing mothers. At 
P12, they were returned to normoxia. Animals were euthanized at P12 to determine 
the area of vaso-obliteration or at P17 to determine the rate of retinal 
revascularization and pre-retinal neovascularization 26, 27. As postnatal weight gain 
has been shown to affect outcome in the OIR model 28, only weight matched (±1 g) 
pups were used in each experiment. Analysis of retinal vasculature was done as 
previously described 29. Briefly, eyes were enucleated, fixed with 4% PFA for one 
hour and retinas dissected. Flat mount retinas were blocked in 10% normal goat 
serum and 10% fetal bovine serum for 2 hours, incubated overnight with isolectin 
GS-IB4 (1:100). Briefly, retinas were imaged using confocal microscopy (Carl Zeiss 
LSM 700) with 10× objective. Pre-retinal neovascular tufts were readily distinguished 
from the superficial vascular plexus by focusing just above the inner limiting 
membrane. Areas of vascular obliteration and pathological neovascularization 
(neovascular tufts) were quantified using Adobe Photoshop CS3.  
Laser-induced choroidal neovascularization (CNV) mouse model: WT and 
Sdc4-/- 6 week old male mice were anesthetized by intraperitoneal injection of 0.15 
ml of a mix of Domitor and Ketamine and pupils dilated with topical administration of 
1 % Tropicamide and 2.5 % Phenylephrine. Three burns per eye were be made by 
laser photocoagulation (680 nm; 100 μm spot diameter; 100 ms duration; 210 mW). 
Only burns that produced a bubble, indicating the rupture of the Bruch's membrane, 




were counted in the study. At day 7 after the laser injury, fundus fluorescein 
angiography (FFA) was performed to measure the area of CNV lesion. The area of 
lesion was then quantified using Imaris Software (Bitplane) and expressed as 
number of pixels. Additionally, at the end of the experiment (day 7) mice were culled, 
choroid-RPE tissue dissected, flat-mounted and stained with lectin GS-II. Confocal 
images were then acquired using a PASCAL laser-scanning confocal microscope 
(Carl Zeiss) followed by volumetric analysis with Imaris software (Bitplane).  
B16F1 melanoma tumor model: B16F1 mouse melanoma cells were obtained from 
HPA Laboratories (UK) and 5x107 cells/ml in 100 μl of PBS were injected sub-
cutaneously into the left flank of 6 week old male WT and Sdc4-/- mice (n=12 per 
group). Mice were left for 7 or 14 days prior to sacrifice by cervical dislocation. A 
longitudinal incision was made from the chest to the genital area, skin was peeled 
and pinned down and tumors were revealed. Photographs were taken with a digital 
camera and tumors excised using scalpel and tweezers. Samples were then 
weighed on a precision balance and diameter measured using a ruler. Samples were 
then snap frozen in liquid nitrogen and stored at -80 °C.  
Skin tumor induction: Sdc4-/- and C57BL/6 WT male mice were treated with 
DMBA and TPA to induce skin tumors according to the established protocol30-32. In 
brief, the backs of 8 week old mice were shaved and 24 h later 50 µg DMBA (7,12-
Dimethylbenz[a]anthracene) (Sigma, Dorset, UK) in 200 µl acetone was applied 
topically on the shaved area of the dorsal skin. After a week, the back skin of the 
mice was treated twice a week with 5 µg TPA (12-O-tetradecanoylphorbol-13-
acetate) (Sigma) in 200 µl acetone for 21 weeks. Tumors (1 mm in diameter or 
larger) were counted twice a week. The fur excluding tumors was carefully shaved 
every two weeks.  
VE-Cadherin internalization assay: Cells were serum starved for 3 hours prior to 
incubation for 1 hour at 4 °C in the presence of an anti-VE-Cadherin antibody (clone 
BV13, eBioscience) conjugated in-house to Alexa555. Unbound antibody was 
washed away using serum free medium. 30 ng/ml of VEGFA was added to cells for 5 
min at 37 °C to allow internalization of VE-Cadherin and bound antibody. For 
analysis of internalized VE-Cadherin, cell surface bound antibody was removed 
using an acid wash (glycine 25 mM, 3% BSA in PBS, pH 2.7). Cells were washed 3X 
with ice cold PBS and fixed with 4 % PFA, 0.25 % glutaraldehyde prior to analysis by 
confocal microscopy. 
Proximity ligation assay: Proximity ligation assay or PLA is a technique that allows 
the identification in situ of spots in which 2 proteins are in close proximity (less than 
40 µm). The PLA experiments were performed as per manufacturer’s instructions 
(Duolink, Sigma Aldrich). Cells were treated as indicated in the results section. 
Following treatments, medium was taken off, cells were washed in PBS at RT, fixed 
in 4 % PFA for 15 min at RT. After a 5 min wash in PBS, PFA was quenched by 
incubating cells with 0.1 M NH4CL for 10 min at RT.  
Evans blue permeability assay: 6-8 week old male mice were anesthetized by i.m. 
injection of 1 ml/kg ketamine (40 mg) and xylazine (2 mg) in saline solution. The 
back skin was shaved using an electric razor. Mice then received Evans Blue dye 
(0.5 % in PBS, 5 μl per g bodyweight) i.v. through the tail vein. Afterwards, 50 µl of 




PBS containing either 100 ng of VEGFA or 100 μg of Bradykinin or PBS alone were 
injected s.c. in the mouse dorsal skin. After 90 min animals were sacrificed by 
cervical dislocation. Dorsal skin was removed and injected sites were cut out as 
circular patches using a metal puncher (~8 mm in diameter). Samples were then 
incubated in 250μl of formamide at 56 °C for 24 h to extract Evans Blue dye from the 
tissues. The amount of accumulated Evans Blue dye was quantified by spectroscopy 
at 620 nm using a Spectra MR spectrometer (Dynex technologies Ltd., West Sussex, 
UK). Results are presented as the optical density at 620 nm (OD620) per mg tissue 
and per mouse. 
Statistical analysis: Data are presented as mean ± s.e.m. and sample sizes are 
reported in each figure legend. Each experiment on animals was performed on at 
least two independent litters of a given genotype. Data were plotted and analyzed for 
statistical significance using Prism 6 (Graphpad software Inc.). Welch’s t-test was 
used when two independent groups were compared. Parametric statistical tests 
(two-tailed t-test and one- or two-way ANOVA) were used to compare the averages 
of two or more groups. Normality and variance were not tested to determine whether 
the applied parametric tests were appropriate. Bonferroni post-hoc test was used 
when we were interested in a set number of planned comparisons (i.e. Control vs 
Mutant(s)). Tukey post-hoc test was used when wanting to make unplanned pairwise 
comparisons (i.e. time-points). Spearman's rank correlation test was conducted to 
test correlation between multiple variables. P-values less than 0.05 were considered 
statistically significant.  






SDC4 is dispensable for vascular development but essential for pathological 
angiogenesis 
As with other syndecan family members, adult Sdc4-/- animals show no 
abnormalities and are phenotypically comparable to wild-type (WT) littermates which 
is suggestive of normal development. In accordance with this hypothesis and in 
keeping with a recent study 20, we observed no major differences in postnatal retinal 
vascular development between WT, Sdc4+/- and Sdc4-/- P6 neonates (Fig. 1 A and 
B). This was also reflected by the absence of any differences in the number of 
arteries and veins between the genotypes (Fig. S1 A). Analysis of parameters such 
as vessel size (Fig. S1 B and C), density (Fig. S1 D), and pericyte coverage (Fig. 
S1 E) in additional adult vascular beds (skin, muscle and connective tissue, Fig. S1 
F) confirmed that Sdc4-/- animals developed a normal vascular network indicating 
that angiogenesis during development was not affected in Sdc4-/- mice. 
We next examined whether angiogenic responses in disease models were affected 
by genetic deletion of SDC4. Oxygen-induced retinopathy (OIR) is a hypoxia-driven 
angiogenesis model that recapitulates features of diabetic retinopathy and 
retinopathy of prematurity33. OIR was performed on 7-day old WT and Sdc4-/- pups 
by exposing them to hyperoxia (75 % O2 for 5 days) leading to the abolition of the 
retinal vasculature, before being returned to normoxia which stimulates a 
neovascular response. Exposure to oxygen led to a comparable loss in retinal 
vasculature in both Sdc4-/- and WT control littermates (Fig. S2 A and B); however, 
upon return to normoxic conditions it was evident that the formation of neovascular 
tufts (a hallmark of pathological angiogenesis) was significantly reduced (~ 40% 
decrease) in the retinas of Sdc4-/- mice compared to WT mice (Fig. 1 C and D). In 
contrast, the physiological neovascular response associated with hypoxia in Sdc4-/- 
animals was only slightly increased as determined by smaller avascular areas in 
these animals 5 days post-hyperoxia compared to WT littermates (Fig. S2 C and D). 
We next investigated whether neovascularization was also attenuated in Sdc4-/- 
mice in the laser-induced choroidal neovascularization (CNV) model which mimics 
neovascular (‘wet’) age-related macular degeneration 34. Laser photocoagulation 
was performed on the eyes of 6-week old WT and Sdc4-/- littermates to stimulate a 
neovascular response in the choroid. Areas of CNV measured 7 days after injury by 
fluorescein angiography were found to be significantly smaller in the eyes of Sdc4-/- 
mice compared to WT mice (Fig. 1 E and F). CNV lesions were predominantly 
composed of ECs on the basis of lectin GS-II staining and we confirmed the 
reduction in lesion volume (~80% decrease) in Sdc4-/- mice using 3D confocal 
reconstruction (Fig. 1 G and H). Together, this data highlights the requirement for 
SDC4 in promoting vessel growth in two models of neovascular eye disease. 
 
Angiogenic defects are not restricted to ocular disease models in Sdc4-/- mice 
We next set out to establish whether the angiogenic defects observed in Sdc4-/- 
mice were restricted to ocular neovascularization or would extend to angiogenic-
driven tumor development models. In the first instance, we injected B16F1 
melanoma cells (which express SDC4, Fig. S3 A) into the flank of WT and Sdc4-/- 
mice. Animals were sacrificed after 2 weeks and both tumor volume and tumor 




weight were significantly reduced in the Sdc4-/- mice compared to WT controls (Fig. 
2 A and B, Fig. S3 B). Critically, immunofluorescence staining of tumor sections for 
EC specific markers CD31 and Podycalyxin revealed vascular structures, with in 
many cases, a well-defined lumen (white arrows in Fig. 2 C and D, Fig. S3 C and 
D), whereas in tumors from Sdc4-/- mice, ECs failed to organize into tubules and 
were more sparsely distributed (Fig. 2 C and D, Fig. S3 C and D). We next tested 
whether this was also the case in a model of epidermal papilloma formation induced 
by two stage treatment with DMBA and TPA, the progression of which, is 
angiogenesis-dependent 30, 35.  At the end point of 19-weeks, WT animals had on 
average 2.4 times more tumors than Sdc4-/- mice and the incidence of large tumors 
was 6-fold higher (Fig. 2 E and F). In the DMBA/TPA model, tumor angiogenesis 
takes place first by increased blood vessel density and later, during papilloma 
formation, by increased blood vessel diameter. Histochemical staining for the EC 
marker CD31 revealed smaller blood vessel lumens in tumors formed in Sdc4-/- 
mice compared to WT (Fig. 2 G and Fig. S3 E). Together this data provides 
compelling evidence that the role of SDC4 in pathological angiogenesis is not 
restricted to neovascular eye disease, but also extends to tumor development. 
 
SDC4 is upregulated during pathological angiogenesis 
To understand further the role of SDC4 in pathological angiogenesis, we next 
compared syndecan gene expression in both the context of developmental and 
pathological angiogenesis in the murine retina. During the early stages of murine 
postnatal development, angiogenesis occurs in the eye leading to the formation of a 
superficial retinal vascular plexus and in C57BL/6 mice this occurs during the first 8 
days after birth. Quantitative rtPCR was performed on retinal mRNA from day P0, 4, 
and 7 neonates to measure the expression of SDC1, -2, -3 and -4 during 
development. SDC1 and -3 showed downregulated expression over time, whereas 
SDC2 and -4 remained unchanged (Fig. 3 A). Next, we examined the transcript 
profile of syndecans in a murine model of retinal pathological neovascularization. 
When pups were subjected to OIR, we detected a marked increase in SDC4 gene 
expression in retinas at P17, the time point at which neovascularization peaks, 
whereas the expression of the other 3 syndecans remained stable (Fig. 3 B). 
Interestingly, this was also the case in both the laser CNV model and in B16F1 
melanomas. SDC4 gene expression was upregulated in retinas 7 days post laser 
injury as compared to control retinas (Fig. S4 A). This was also the case when 
SDC4 gene expression was analyzed in B16F1 melanomas (7 days post injection), 
when compared to B16F1 cells in culture (Fig. S4 B). These increases in gene 
expression were not a characteristic of the other SDC family members, the exception 
being SDC3 in the B16F1 melanoma model, which according to previous studies, 
could be immune cell derived36. 
To investigate whether SDC4 was upregulated in a human disease setting, we 
analyzed its expression in the retinal neovascular membranes that develop in human 
diabetic retinopathy patients. Neovascular membranes were collected from type I 
diabetes patients suffering from retinopathy, who had either already developed or 
had threatening tractional retinal detachment due to fibro-vascular proliferation. 
These tissue samples represented the end stage of the disease, but still contained 
regions with active pathological angiogenesis. Histological analysis of adjacent 
tissue sections revealed SDC4 expression predominantly associated with blood 




vessels (CD31+ areas). Moreover, immunostaining for VEGFR2 (a marker of 
pathological immature blood vessels) and CD31 revealed that SDC4 expression 
strongly correlated with CD31+/VEGFR2high blood vessels, whereas only moderate 
expression was detected in CD31+/VEGFR2low areas (Fig. 3 C and D, Fig. S4 C). 
We conclude from this that, at least in the context of neovascular eye disease, SDC4 
expression positively correlates with newly formed, immature blood vessels during 
pathological angiogenesis in both murine models and in human neovascular 
disease. 
 
Angiogenic responses to VEGFA require SDC4 
As the principal driver of angiogenesis in the models described above is VEGFA, we 
therefore wanted to explore whether responsiveness to VEGFA was a factor in the 
phenotypes we observed in Sdc4-/- animals. WT and Sdc4-/- mice were injected with 
Matrigel containing VEGFA which triggered an angiogenic response in WT mice as 
evidenced by plug hemoglobin content. In contrast, an angiogenic response was 
notably reduced in VEGFA-containing plugs from Sdc4-/- mice (Fig. 4 A and B). We 
next adopted a more reductive approach in which tissue explants from both choroid 
membranes and aortas from Sdc4-/-, Sdc4+/- and WT littermates were embedded in 
a collagen I matrix and exposed to VEGFA. In both cases, significantly more 
angiogenic sprouts emerged from WT, compared to Sdc4-/- explants (Fig. 4 C to E). 
Interestingly, explants from heterozygous (Sdc4+/-) mice exhibited an intermediate 
phenotype indicating that the angiogenic response to VEGFA associated with SDC4 
is subject to gene dosage effects. WT levels of angiogenic sprouting was restored in 
Sdc4-/- null aortic rings transduced with lentiviruses to re-express full length SDC4 
(Fig. 4 F), confirming the requirement of SDC4 for this response. Of importance, 
angiogenic responses to an alternative pro-angiogenic factor FGF2 were comparable 
between WT and Sdc4-/- animals, in both the Matrigel plug and the aortic ring 
assays (Fig. S5 A to C). 
On the basis of these results, we hypothesized that endothelial SDC4 could be 
involved in the specific regulation of VEGFA-dependent EC responses. To this end, 
we analyzed EC migration by light microscopy and observed that while primary 
Sdc4-/- lung ECs were able to migrate in a growth factor-rich environment (FBS), 
albeit slightly less than WT ECs, their migratory response to VEGFA stimulation was 
negligible (Fig. S4 D and E). We further demonstrated that EC migration in response 
to VEGFA could be restored in Sdc4-/- ECs upon re-expression of full length SDC4 
(Fig. 4 G) and, interestingly, also by a mutant form of SDC4 lacking the 
glycosaminoglycan chains (SDC4HA-ΔGAG), suggesting that GAG chains were not 
required for this function. These data suggest that the pro-angiogenic role of SDC4 
in pathological neovascularization is linked to defective EC responses to VEGFA. 
 
SDC4 resides at EC junctions and is redistributed in response to VEGFA 
Previous studies have indicated that SDC4 does not impact on VEGFR2/VEGFA 
signaling 20. To confirm this, we looked at VEGFR2 phosphorylation in response to 
VEGFA in primary lung ECs from WT and Sdc4-/- mice and observed no differences 
(Fig. 5 A). This was also true of the downstream signaling kinase Erk1/2 which was 
also phosphorylated to the same extent in WT and Sdc4-/- ECs in response to 




VEGFA (Fig. 5 A). We also measured cell surface expression of VEGFR2 in WT and 
Sdc4-/- cells and found this to be the same (Fig. S5 F). 
In order to understand the role of SDC4 in ECs during angiogenesis, we examined 
its localization in HUVECs. We expressed an eGFP tagged form of SDC4 in ECs 
(eGFP inserted between I32 and D33 of murine SDC4 cDNA, Fig. 5 B), and observed 
a pool of SDC4-eGFP localized to EC junctions (Fig. 5 B, white arrows). 
Interestingly, stimulation of these transfected HUVECs with VEGFA led to a 
substantial redistribution of SDC4-eGFP (Fig. 5 B, Supplemental movies 1 and 2) 
which was not the case in unstimulated cells. To explore this further we used 
fluorescence recovery after photo-bleaching (FRAP) to measure the kinetics of 
diffusion of SDC4-eGFP with and without VEGFA stimulation. We performed photo-
bleaching of SDC4-eGFP at EC-EC contacts and observed the rate of recovery of 
fluorescence both under basal and VEGFA-stimulated conditions. Recovery of 
SDC4-eGFP fluorescence was significantly enhanced by the addition of VEGFA 
(Fig. 5 C to E), suggesting that the addition of VEGFA alters the functional status of 
SDC4. Previous studies have shown that phosphorylation of SDC4 at Y180 by Src 
kinase is essential for regulating the trafficking of integrins in fibroblasts37. To this 
end, we asked whether phosphorylation of this residue was important for the VEGFA 
stimulated response observed above with Sdc4-eGFP. We generated a mutant form 
of Sdc4-eGFP in which Y180 of SDC4 was mutated to an Alanine to make it 
nonphosphorylatable (SDC4(Y180-A)-eGFP). Interestingly, recovery of SDC4(Y180-A)-
eGFP fluorescence was as rapid as SDC4-eGFP treated with VEGFA, regardless of 
whether they were treated with VEGFA or not (Fig. 5 C to E). Enhanced 
fluorescence recovery rates are often associated with molecules dissociating from a 
complex, so these results suggest that VEGFA stimulates the disassociation of 
SDC4 from a molecular complex at EC junctions and that this association requires 
SDC4 to be phosphorylated at Y180. Taken together, these data indicate that not only 
is a pool of SDC4 resident at EC junctions, but its function is driven by VEGFA 
signaling. 
  
SDC4 is required for VEGFA-induced VE-Cadherin internalization and hyper-
permeability 
We further explored the enrichment of SDC4 at EC cell-cell contacts, this time in 
untransfected cells. Here, consistent with our earlier observation in cells expressing 
Sdc4-eGFP, we found a pool of SDC4 at EC junctions co-localizing with both VE-
Cadherin and VEGFR2 (Fig. 6 A). We next performed Proximity Ligation Assays 
(PLA) on SDC4 and VE-Cadherin and detected interactions between these two 
molecules under basal conditions (Fig. 6 B). This interaction declined after 2 and 5 
mins following VEGFA treatment and recovered after 10 minutes (Fig. 6 C). We 
confirmed an interaction between SDC4 and VE-Cadherin by performing immuno-
precipitation experiments with HA-tagged forms of SDC4 expressed in HUVECs. VE-
Cadherin was detectable in anti-HA immuno-precipitates from cells expressing 
SDC4HA or SDC4HA-ΔGAG, suggesting that SDC4 GAG chains are not required for 
this interaction. Interestingly, more VE-Cadherin was present in immuno-precipitates 
from cells expressing SDC4HA-Y180-F a phosphomimetic, compared to the 
nonphosphorylatable form SDC4HA-Y180-A (Fig. S6 A). Furthermore, less VE-
Cadherin was evident in immuno-precipitates from SDC4HA transduced cells 
following treatment with VEGFA (Fig. S6 B). Collectively, this data suggests that 




phosphorylated SDC4 interacts with VE-Cadherin, and that treatment with VEGFA 
leads to dephosphorylation of SDC4 and the disruption of this interaction. 
This led us to postulate that SDC4 could play a role in the regulation of VEGFA-
induced VE-Cadherin internalization and tested this hypothesis in an antibody-
feeding assay. We found that primary Sdc4-/- ECs displayed reduced VE-Cadherin 
internalization following exposure to VEGFA compared to WT ECs (Fig. 6 D and E). 
Additionally, cell surface biotinylation experiments revealed that whilst in WT cells 
biotinylated cell surface VE-Cadherin is reduced after VEGFA treatment, this was not 
the case with Sdc4-/- MLECs (Fig. S6 C). In line with this observation, newly-formed 
blood vessels in retinas from Sdc4-/- OIR mice had fewer intracellular VE-cadherin+ 
vesicles compared to WT vasculature, whereas VE-cadherin immunostaining was 
more discontinuous and VE-Cadherin+ vesicles were more abundant (Fig. S7). 
Expression of SDC4HA, and SDC4HA-Y180-F all restored VE-Cadherin 
internalization responses to VEGFA in Sdc4-/- MLECs, which was not the case in 
SDC4HA-Y180-A transduced cells (Fig. S8). Since VEGFA-dependent endocytosis of 
VE-Cadherin from the EC adherens junctions is a known to trigger of vascular 
permeability in vivo 38, we next measured the leakage of albumin-bound Evans blue 
from the dermal microvasculature in response to VEGFA and bradykinin (a known 
vasodilator) in WT and Sdc4-/- animals. Results showed that vascular leakage in 
response to VEGFA was significantly reduced in Sdc4-/- animals (Fig. 6 F and G). 
Together, our data identifies a novel association between SDC4 and VE-Cadherin 
that is modulated by VEGFA. We further reveal that SDC4 is required for VEGFA-
induced VE-Cadherin internalization and hyper-permeability.  
 
Soluble SDC4 reduces VEGFA induced VE-Cadherin internalization in a pre-
clinical model of wet AMD 
Lastly, we explored whether a soluble form of SDC4 (referred to as solS4, 
corresponding to the complete ectodomain of SDC4) could interfere with its pro-
angiogenic role, in particular by disrupting the SDC4/VE-cadherin interaction. Using 
antibody-feeding approaches, we found that addition of solS4 to a monolayer of WT 
ECs prevented VEGFA-driven VE-Cadherin internalization (Fig. 7 A and B). 
Moreover, incubation of HUVECs with solS4 led to a reduction in PLA puncti 
between SDC4 and VE-Cadherin at EC junctions (Fig. S9 A), indicating that it may 
be disrupting the SDC4/VE-Cadherin complex. In addition, solS4 treatment also 
abolished VEGFA-driven EC migration. This is in contrast to ECs pre-treated with 
soluble SDC2 (solS2), the syndecan most structurally similar to SDC4, which 
maintained responsiveness to VEGFA (Fig. 7 C). As was the case with Sdc4-/-  
primary ECs, no impact on VEGFA signaling was observed in ECs stimulated with 
VEGFA in the presence or absence of solS4 (Fig. S9 B and C).We also observed 
reduced sprouting when aortic explants where treated with solS4 (Fig. 7 D and E). 
We next assessed whether solS4 could be therapeutically beneficial as an anti-
angiogenic compound, by testing its efficacy in the laser-induced CNV model in 
comparison to Aflibercept (Eylea®, Regeneron), one of the current standard 
therapies for neovascular AMD patients. We found that a single injection of solS4 at 
day 0 post-laser injury reduced the angiogenic response at day 7 by almost 50% 
compared to vehicle (PBS) control, achieving similar anti-angiogenic activity to that 
of Aflibercept (Fig. 7 F and G). Altogether, these results indicate that delivery of 




solS4 decreases VE-Cadherin internalization, EC migration and reduces pathological 
angiogenesis in a pre-clinical murine model of neovascular AMD. 
  






In this work we have performed detailed analysis of both post-natal and adult micro-
vasculature in Sdc4-/- animals and found that vascular development is not affected 
by genetic deletion of SDC4. However, we showed in multiple murine disease 
models (diabetic retinopathy, wet AMD, melanoma and epidermal carcinogenesis) 
that SDC4 is required for robust pathological angiogenesis. This difference can be 
explained by SDC4 being differentially expressed during these two chronologically-
distinct processes. In fact, our data reveals that SDC4 was the only syndecan 
member which was upregulated in models of pathological angiogenesis and 
importantly, its expression correlated with immature, pathological vessels formed in 
the retinas of diabetic retinopathy patients. The existence of hypoxia- 39 and 
inflammation-related regulatory elements (i.e. NF-κB 40 within the Sdc4 promoter 
region supports the concept that the expression and activity of this proteoglycan is 
driven by responses to hypoxia and inflammation, concomitant with pathological 
scenarios and important pro-angiogenic stimuli.  
In the in vivo models described in this study, the primary driver of angiogenesis is 
VEGFA. We therefore explored the responses of Sdc4-/- cells and tissues in VEGFA 
stimulated angiogenesis assays (e.g. VEGFA-induced cell migration, tissue explant 
sprout formation) and found them to be impaired. This suggests that the defects we 
observed are linked to the angiogenic pathways driven by VEGFA. Importantly, 
normal angiogenic responses could be restored when SDC4 was expressed in Sdc4-
/- cells and tissues. Our initial hypothesis was that SDC4 was acting as co-receptor 
between VEGFA and VEGFR2 through its HS chains. Recent studies suggest that 
this is the case for SDC4, VEGFC and VEGFR3 during pathological 
lymphangiogenesis 41. However, we discounted this hypothesis since, consistent 
with other studies, we observed no reduction in either phosphorylation of VEGFR2 or 
major signaling kinases downstream of this receptor (Erk1/2) in Sdc4-/- ECs treated 
with VEGFA. These findings are in agreement with the observation that VEGFA 
signaling requires SDC2, not SDC4, owing to differences in the levels of 6-O-
sulphation on the HS chains of these molecules 20.  
An excess of SDC4 achieved either by genetic means or via exogenous addition 
within proteo-liposomes leads to increased angiogenesis and improved therapeutic 
outcomes in models of ischemic injury and myocardial infarction23, 25, 42. These 
findings support the idea that upregulation of SDC4 expression is an important 
component in angiogenic responses. Furthermore, silencing of SDC4 leads to an 
attenuation of angiogenic responses in cell-based assays 43. Pro-angiogenic roles for 
SDC4 have been reported, particularly, in augmenting FGF2 signaling 23, 25, 42. The 
relationship between HS and FGF2 is well established and it is likely that SDC4 HS, 
when in abundance in these models, is responsible for enhanced FGF2 driven 
cellular responses. Both 2-O and 6-O sulphated HS can promote FGF2 signaling 44-
47 whereas there is a distinct requirement for 6-O sulphation on HS chains for 
promoting the VEGFR2/VEGFA interaction20. The more promiscuous HS binding 
requirements of FGF2 mean there is likely to be redundancy in the system and other 
HSPGs could be the source of the HS required to engage FGF2 in Sdc4-/- animals 
which may explain the lack of developmental angiogenic defects in these mice. In 
common with other studies we did not observe an effect on FGF2 induced 
angiogenesis in Sdc4-/- animals 20. Collectively this suggests that, in the absence of 




SDC4, VEGFA/VEGR2 signaling is unperturbed and this led us to speculate that 
SDC4 may have a role in pathological angiogenesis and is regulated by the 
VEGFA/VEGFR2 axis. 
We demonstrated that SDC4 localizes to EC cell-cell contacts and co-localizes with 
the junctional protein VE-Cadherin. This is in keeping with recent proteomic studies 
in which SDC4 was found to be associated with EC junctional proteins 48. EC 
adherens junctions are a complex assemblage of both junctional and cytoskeletal 
proteins and many of the molecules involved also constitute focal adhesion 
complexes, in which SDC4 is a known component 49. Furthermore, numerous 
studies have identified roles for SDC4 in cytoskeletal rearrangements and changes 
in the actin cytoskeleton in a variety of cell types, including ECs 43. The disassembly 
of these structures is a critical early step in angiogenesis 50 and we showed that ECs 
null for SDC4 exhibited defective VE-Cadherin internalization away from junctions in 
response to VEGFA stimulation. This was also reflected in defective vascular 
permeability responses in vivo. Our data revealed that under basal conditions SDC4 
is in complex with VE-Cadherin, and this complex is disrupted rapidly following 
VEGFA stimulation.  The presence of SDC4 in this complex is clearly an important 
precursor for efficient VE-Cadherin trafficking since when SDC4 is absent (e.g. in 
Sdc4-/- animals or ECs) this process was inhibited substantially. The 
phosphorylation status of SDC4, specifically on residue Y180, is also important in 
regulating this process. Mutant forms of SDC4 in which this residue is mutated to 
Alanine did not complex effectively with VE-Cadherin and failed to restore efficient 
VE-Cadherin trafficking in Sdc4-/- ECs. Conversely, phosphomimetic mutants 
complexed with VE-Cadherin were capable of restoring VEGFA driven VE-Cadherin 
internalization. We therefore speculate that in response to VEGFA, SDC4 is 
dephosphorylated leading to a disruption of the SDC4/VE-Cadherin complex. 
Phosphorylation of this residue by c-SRC is an important control point of integrin 
trafficking 37 and it is not inconceivable that this may also be linked to the findings 
reported here, since β1 integrin activation state influences VE-cadherin localization 
51, 52. Moreover, the expression of SDC4 is required for the expression of junctional 
Cadherin-11 in fibroblasts 53 and in calcium signaling 54. These studies, in 
conjunction with our findings suggests that SDC4 may be involved with other 
members of the Cadherin family in other cell types.  
Our studies indicate that SDC4 is essential for efficient VE-Cadherin internalization 
in response to VEGFA and we show that the delivery of soluble SDC4 inhibits this 
process. This is in contrast other reported observations in which thrombin-cleaved 
fragments of both SDC3 and SDC4 extracellular core protein promote EC junctional 
reorganization in cultured ECs55. Regulatory sequences within syndecan 
extracellular core proteins have been identified in all 4 syndecan family members 
and they can impact on EC behaviour56. The soluble form of SDC4 used in this study 
comprises the entire extracellular core protein. A possible explanation for the 
disparity in these observations is that fragments of SDC4 ectodomain may have 
different properties to the full-length version. In addition, there may also be possible 
synergism between SDC4 and SDC3 ectodomain fragments, the full length of which 
can also modulate angiogenesis57. 
We also show that soluble SDC4 can reduce both VEGF-driven angiogenesis and 
hyper-permeability in vivo. Neovascularization and subsequent vascular leakage 
from angiogenic blood vessels is an important and exacerbating factor in 
neovascular eye disease 58. Furthermore, angiogenesis blocking strategies are in 




use for the treatment of a number of tumors. The most common therapeutic options 
involve targeting VEGFA either using antibodies or receptor-mimicking recombinant 
proteins. Although successful, these therapies are not without limitations, particularly 
with regard to patient non-response in ophthalmic indications and a significant side-
effect profile when administered systemically in treating cancer 59, 60. We 
demonstrate that SDC4 acts downstream of the VEGFA/VEGFR2 axis and 
application of a solSDC4 while disrupting the SDC4/VE-cadherin interaction has 
negligible impact on the phosphorylation status of key signaling kinases within ECs. 
Potentially therefore at least in the instances where anti-angiogenic therapies are 
administered systemically, fewer adverse effects might be observed in targeting 
SDC4/VE-Cadherin, particularly as SDC4 seems only to be upregulated on ECs 
during pathological scenarios. The rationale for targeting SDC4 for therapeutic 
benefit has been demonstrated in other disease models. Antibodies against SDC4 
have been shown to block SDC4 dimerization in response to IL-1β stimulation, and 
these have a positive impact in models of inflammatory arthritis61. Furthermore, use 
of recombinant proteins derived from SDC4 binding partners have also proven 
efficacious in disease models. The Ig1 and 2 repeats from the protein tyrosine 
phosphatase receptor sigma (PTPRρ) have also been shown to inhibit signaling of 
this receptor resulting in improved outcomes in collagen-induced arthritis models62. 
Whether these reagents could be used to target pathological angiogenesis remains 
unexplored, but strongly support the idea that SDC4 could be targeted for 
therapeutic benefit in disease settings. 
Taken together, our study identifies SDC4 as an essential regulatory component in 
VEGFA-induced VE-cadherin internalization from EC junctions during pathological 
angiogenesis. We believe these results provide significant further insight into the 
molecular events controlling neovascularization and hyper-permeability responses in 
diseases. The formation of abnormal blood vessels is a feature of cancer, 
neovascular eye diseases and chronic inflammatory conditions, which implies that 
SDC4 blocking strategies may have the potential to be applied in these contexts to 
either improve or offer a more selective alternative to existing therapies.  
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• Syndecan-4 null mice are protected in models of neovascular eye diseases 
and skin tumor models due to defective angiogenesis. 
• Syndecan-4 expression is upregulated during pathological angiogenesis in 
mice and is selectively enriched in immature blood vessels in the retinas of diabetic 
retinopathy patients.  
• A pool of Syndecan-4 resides at endothelial cell junctions, and has no role in 
VEGFA/VEGFR2 signaling, but rather, is downstream of this interaction.  
• Syndecan-4 null animals and cells show inefficient VEGFA-induced VE-
Cadherin internalization and this is reflected in vivo by aberrant vascular permeability 
responses to VEGFA. 












Figure 1. Pathological angiogenesis in murine models of neovascular eye 
disease requires SDC4. Developmental retinal angiogenesis in Sdc4-/- mice 
proceeds at the same rate as WT. A, Micrographs comparing retinal micro-vessel 
formation between Sdc4-/- and WT p6 neonates (Scale bar, 1 mm). B, Retinas were 
stained with isolectin GS-IB4, and the distance between the optical nerve and the 
angiogenic front (arrows) was measured and the extent of retinal angiogenesis 
between WT, Sdc4+/- and Sdc4-/- p6 neonates compared (n=10-15 
animals/genotype). C, Neovascular tuft formation in response to OIR is reduced in 
Sdc4-/- p17 neonates. Representative micrographs of retinas stained with isolectin 
GS-IB4  (scale bar = 500µm). D, Quantification of neovascular tufts (~40 
eyes/group). E, Micrographs showing Sdc4-/- animals exhibit less angiogenesis in 
the laser induced CNV model as evident from reduced lesion area (n=6-8 
animals/group, Scale bar = 2.4 mm). F, Densitometry measurements of CNV lesions 
comparing responses between WT and Sdc4-/- animals. G, Staining of CNV lesions 
with lectin GS-II followed by 3D confocal reconstruction. H, CNV lesion volume was 
calculated using Imaris Bitplane software on the basis of lectin GS-II staining. n=5-6 
animals for each group. Centre line, median. Plus sign, mean. Error bars indicate 
min and max values. *P < 0.05; **P < 0.01; ***P<0.001. 
 
Figure 2. Tumor angiogenesis is impaired in Sdc4-/- animals. A, Micrographs of 
B16F1 melanomas from WT and Sdc4-/- animals showing reduced tumor volume as 
quantified in B, (n=5-6 mice/group). C, Tumor vessels (arrowheads) appear in WT 
sections but are not obvious in B16F1 melanomas from Sdc4-/- mice (Ki-67, blue; 
CD31 red, scale bar, 100 µm), D, quantification of tumor vessel coverage 
(n=5/group, 3 images/animal). E, Papilloma formation is reduced in Sdc4-/- mice in 
the DBMA/TPA model. Micrographs of animals (left) and sections of skin (right, H&E 
stained) from WT and Sdc4-/- animals at week 19 (scale bar, 2 mm). F, Reduced 
size of papillomas at end of the experiment (n=7 mice/group). G, Tumor sections 
from WT and Sdc4-/- animals were immuno-stained for the EC marker CD31and 
vessel width was measured.  *P < 0.05; ***P < 0.001. 
 
Figure 3. SDC4 expression is upregulated during pathological angiogenesis. A, 
Syndecan gene expression profile during early stages of murine retinal 
angiogenesis. Eyes were enucleated on postnatal day 0, 4 and 7, mRNA extracted 
and quantified by qPCR. B, Syndecan gene expression in neonates subjected to 
OIR (P12 vaso-obliteration phase, P17 angiogenic phase) and in untreated controls. 
Centre line, median. Plus sign, mean. N=4-6 animals for each group. Error bars 
indicate min and max values. *P < 0.05; **P < 0.01. (C, and D,) Consecutive sections 
of human proliferative diabetic retinopathy membrane stained for CD31 marker of 
blood vessels), VEGFR2 (marker of new immature vessels), and SDC4. Regions of 
high VEGFR2 expression on ECs have correspondingly high levels of Sdc4 




expression C, and this is not the case on sections where there is low VEGFR2 
expression D,. Scale bar, 200 μm. Images are representative of n=6 patients. 
 
Figure 4. Functional angiogenic responses to VEGFA are impaired in Sdc4-/- 
explants and ECs. A, Matrigel supplemented with PBS or VEGFA (50 ng) was 
injected subcutaneously in the flank of WT or Sdc4-/- mice. Images are 
representative of plugs extracted 7 days post-injection. Scale bar, 1 cm. B, Plug 
vascularity was expressed as the amount of haemoglobin released from the plugs 
per ml of Matrigel and normalized for the plug weight. n=5-6 animal for each group (2 
plugs per animal). C, Fragments (1 mm2) of choroid were dissected from adult WT, 
Sdc4+/- and Sdc4-/- littermates and cultured as explants in VEGFA-containing 
medium. Explants were stained with lectin GS-II (red) and anti-αSMA (green) after 7 
days in culture and imaged using a Zeiss LSM 800 confocal laser scanning 
microscope with a 10x objective. Arrows show angiogenic sprouts. Scale bar, 100 
µM. D, Sprouting was quantified by manually counting the number of sprouts per 
explant. n=5-6 animal for each group, 10 explants per animal. E, Quantification of 
sprout formation from aortic ring explants (n=5-6 animal for each group, 15-20 rings 
per animal). F, Sdc4-/- aortic rings were lentivirally transduced to express either 
eGFP (EV) or SDC4 (SDC4), n=3 animals per group, 5-6 explants per animal. G, 
Sdc4-/- MLECs were lentivirally transduced to express either SDC4 or SDC4∆GAG, 
and the migration of these cells compared to WT and Sdc4-/- in scratch wound 
migration assays. Cells were serum starved prior to the addition of VEGFA (10 
ng/ml) and images at 0 hours and 9 hours are shown. Scale bar, 200 µm. Migrated 
area was calculated by subtracting the final scratch area from the initial scratch area 
using ImageJ. n=3-4, *p<0.05, **p<0.01, ****p<0.0001. 
Figure 5. SDC4 acts down stream of VEGFA/VEGFR2 signaling. A, Western 
blots of either WT or Sdc4-/- MLEC lysates harvested at different time points after 
VEGFA stimulation. Levels of phoshpo-VEGR2 and Erk1/2 were assayed. B, The 
complete coding sequence of eGFP was inserted into murine SDC4 between I32 and 
D33 and cloned into lentiviral expression vectors (diagram). Fluorescence confocal 
images of transfected HUVECS showing SDC4-eGFP localizes to EC junctions, and 
this is altered by VEGFA stimulation. Images correspond to the first and last of a 5 
minute time lapse video (see Supplemental Movies 1 and 2). Cells were stimulated 
as indicated. C, Confocal images of FRAP of HUVECs expressing SDC4-eGFP or 
SDC4 Y180-A-eGFP at the time points indicated in the presence or absence of 
VEGFA stimulation. FRAP and image capture were performed using a Zeiss LSM 
800 confocal laser scanning microscope with a 63x objective. D, Quantification of 
fluorescence recovery of Sdc4-eGFP and E, plots of the half-life of recovery for each 
of the treatments. n=3, **p<0.01. 
Figure 6. SDC4 is required for efficient VE-Cadherin redistribution at EC 
junctions in response to VEGFA. A, Immunofluorescence staining for endogenous 
SDC4 (green) shows co-localization with VE-Cadherin (red) and VEGFR2 (purple) at 
EC junctions. Scale bar, 20 µm. B, Confocal micrographs of HUVECs showing 
proximity ligation puncti on the cell surface (red dots) between SDC4 and VE-




Cadherin (nuclei, blue; VE-Cadherin, green). An example of junctional punctum 
(yellow arrow) and a non-junctional punctum (white arrow) is shown on the right 
hand micrograph. Scale bar, 10 µm. C, Quantification of SDC4/VE-Cadherin PLA 
puncta on the cell surface over time after VEGFA stimulation (10ng/ml). D, MLECs 
from WT and Sdc4-/- mice were washed with PBS and incubated with anti-VE-
Cadherin antibody at 4 °C for 1 hour. Unbound antibody was washed away and cells 
stimulated with VEGFA (30 ng/ml) for 10 min at 37 °C to promote VE-Cadherin 
internalization. Cells were then subjected to an acid wash to remove cell surface 
antibody. VE-Cadherin (red), DAPI (blue). Scale bar, 20 μm. E, Images of MLECs 
treated with VEGFA and acid-washed were analyzed on Imaris software and VE-
cadherin+ vesicles were counted and divided by the number of nuclei in the field of 
view. n=3. Images are representative of one experiment where 9 images per 
condition were analyzed F, Evans blue was injected into the tail vein of WT and 
Sdc4-/- mice, followed by subcutaneous injections of PBS, VEGFA (100 ng) or 
Bradykinin (BK, 100 μg). Images show the local extravasation of the dye from 
underneath the skin 90 minutes post-injection, white circles indicate the approximate 
injection area. G, Skin punches corresponding to the injection sites were collected 
and Evans blue extracted in formamide overnight. Permeability was quantified by 
measuring the optical density at 620 nm of the skin extracts and values were 
normalized on the basis of tissue weight. n=6-8 animals per condition. Data are 
mean ± s.e.m. *P < 0.05; **P < 0.01; ****P<0.0001. Statistical comparisons were 
made between PBS and treatments within the same genotype unless otherwise 
indicated. 
Figure 7. The extracellular core protein of SDC4 (solS4) inhibits VEGFA 
induced VE Cadherin internalization in vitro and choroidal neovascularization 
in vivo. A, Confocal images of VE-Cadherin antibody ‘washout’ experiments. WT 
MLECs were washed with PBS and incubated with anti-VE-Cadherin antibody at 4 
°C for 1 hour. Unbound antibody was washed away and cells stimulated with VEGFA 
(30 ng/ml) for 10 min with or without SolS4 (3.5 nM) at 37 °C to promote VE-
Cadherin internalization followed by acid washing. VE-Cadherin (white). Scale bar, 
20 μm. B. Images of MLECs treated with VEGFA and acid-washed were analyzed 
on Imaris software and VE-cadherin+ vesicles were counted and divided by the 
number of nuclei in the field of view. 9 images per condition were analyzed. n=3 
Scale bar, 20 μm. C. HUVECs were scratched and incubated in serum-free media 
with or without VEGFA (20 ng/ml) and with or without SolS4 or solS2 (3.5 nM) for 16 
hours. Migrated area was calculated by subtracting the final scratch area to the initial 
scratch area using ImageJ. n=3. D, Micrographs of C57BL6 murine aortic rings 
embedded in Collagen I and cultured as explants in VEGFA-containing medium with 
or without solS4 (3.5 nM) for 7 days. E, Manual quantification of angiogenic sprouts. 
(n=4, 5-15 rings/condition). Scale bar, 10 μm. F, Fundus fluorescein angiograms of 
WT animals at day 7 post laser induced CNV. Intravitreal injection of 1 µl of either 
PBS, Aflibercept (10 µg) or solS4 (100 ng) were performed at day 0 directly after 
laser burns were applied.  Scale bar, 2.4 mm. G, The CNV lesion areas were 
quantified using ImageJ, each dot represents the average of 3 lesions per eye. n=7-9 
animals per condition. Data are means and error bars indicate SEM in B, C and G 
and min and max values in E. *P < 0.05; **P < 0.01; ***P<0.001. 
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Pathological angiogenesis in murine models of neovascular eye disease requires SDC4. 
Developmental retinal angiogenesis in Sdc4-/- mice proceeds at the same rate as WT. (A) Micrographs 
comparing retinal micro-vessel formation between Sdc4-/- and WT p6 neonates (Scale bar, 1 mm). (B) 
Retinas were stained with isolectin GS-IB4, and the distance between the optical nerve and the angiogenic 
front (arrows) was measured and the extent of retinal angiogenesis between WT, Sdc4+/- and Sdc4-/- p6 
neonates compared (n=10-15 animals/genotype). (C) Neovascular tuft formation in response to OIR is 
reduced in Sdc4-/- p17 neonates. Representative micrographs of retinas stained with isolectin GS-IB4 
(scale bar= 500µm). (D) Quantification of neovascular tufts (~40 eyes/group). (E) Micrographs showing 
Sdc4-/- animals exhibit less angiogenesis in the laser induced CNV model as evident from reduced lesion 
area (n=6-8 animals/group, Scale bar= 2.4 mm). (G) Staining of CNV lesions with lectin GS-II followed by 
3D confocal reconstruction. (H) CNV lesion volume was calculated using lmaris Bitplane software on the 
basis of lectin GS-II staining. n=5-6 animals for each group. Centre line, median. Plus sign, mean. Error 
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Tumor angiogenesis is impaired in Sdc4-/- animals. (A) Micrographs of B16F1 melanomas from WT 
and Sdc4-/- animals showing reduced tumor volume as quantified in (B) (n=5-6 mice/group). (C) Tumor 
vessels (arrowheads) appear in WT sections but are not obvious in B16F1 melanomas from Sdc4-/- mice 
(Ki-67, blue; CD31 red, scale bar, 100 µm), (D) quantification of tumor vessel coverage (n=5/group, 3 
images/animal). (E) Papilloma formation is reduced in Sdc4-/- mice in the DBMA/TPA model. Micrographs 
of animals (left) and sections of skin (right, H&E stained) from WT and Sdc4-/- animals at week 19 (scale 
bar, 2 mm). (F) Reduced size of papillomas at end of the experiment (n=7 mice/group). (G) Tumor sections 
from WT and Sdc4-/- animals were immuno-stained for the EC marker CD31and vessel width was 
measured. *P < 0.05; ***P < 0.001. 
Figure 3 
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SDC4 expression is upregulated during pathological angiogenesis. (A) Syndecan gene expression 
profile during early stages of murine retinal angiogenesis. Eyes were enucleated on postnatal day 0, 4 and 
7, mRNA extracted and quantified by qPCR. (8) Syndecan gene expression in neonates subjected to OIR 
(P12 vaso-obliteration phase, P17 angiogenic phase) and in untreated controls. Centre line, median. Plus 
sign, mean. N=4-6 animals for each group. Error bars indicate min and max values. *P < 0.05; **P < 0.01. 
(C and D) Consecutive sections of human proliferative diabetic retinopathy membrane stained for CD31 
marker of blood vessels), VEGFR2 (marker of new immature vessels), and SDC4. Regions of high 
VEGFR2 expression on ECs have correspondingly high levels of Sdc4 expression (C) and this is not the 
case on sections where there is low VEGFR2 expression (D). Scale bar, 200 µm. Images are 
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+ SDC4HA- !'.GAG 
Functional angiogenic responses to VEGFA are impaired in Sdc4-I- explants and ECs. (A) Matrigel 
supplemented with PBS or VEG FA (50 ng) was injected subcutaneously in the flank of WT or Sdc4-I- mice. 
Images are representative of plugs extracted 7 days post-injection. Scale bar, 1 cm. (B) Plug vascularity was 
expressed as the amount of haemoglobin released from the plugs per ml of Matrigel and normalized for the 
plug weight. n=5-6 animal for each group (2 plugs per animal). (C) Fragments (1 mm2) of choroid were 
dissected from adult WT, Sdc4 +/- and Sdc4-I- littermates and cultured as explants in VEGFA-containing 
medium. Explants were stained with lectin GS-II (red) and anti-aSMA (green) after 7 days in culture and 
imaged using a Zeiss LSM 800 confocal laser scanning microscope with a 1 Ox objective. Arrows show 
angiogenic sprouts. Scale bar, 100 µM. (D) Sprouting was quantified by manually counting the number of 
sprouts per explant. n=5-6 animal for each group, 10 explants per animal. (E) Quantification of sprout 
formation from aortic ring explants (n=5-6 animal for each group, 15-20 rings per animal). (F) Sdc4-I- aortic 
rings were lentivirally transduced to express either eGFP (EV) or SDC4 (SDC4 ), n=3 animals per group, 5-6 
explants per animal. (G) Sdc4-I- MLECs were lentivirally transduced to express either SDC4 or SDC4!lGAG, 
and the migration of these cells compared to WT and Sdc4-I- in scratch wound migration assays. Cells were 
serum starved prior to the addition of VEG FA (10 ng/ml) and images at O hours and 9 hours are shown. 
Scale bar, 200 µm. Migrated area was calculated by subtracting the final scratch area from the initial scratch 
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SDC4 acts down stream of VEGFANEGFR2 signaling. (A) Western blots of either WT or Sdc4-I- MLEC 
lysates harvested at different time points after VEGFA stimulation. Levels of phoshpo-VEGR2 and Erk1/2 
were assayed. (B) The complete coding sequence of eGFP was inserted into murine SDC4 between 132 
and 0 33 and cloned into lentiviral expression vectors (diagram). Fluorescence confocal images of 
transfected HUVECS showing SDC4-eGFP localizes to EC junctions, and this is altered by VEGFA 
stimulation. Images correspond to the first and last of a 5 minute time lapse video (see Supplemental 
Movies 1 and 2). Cells were stimulated as indicated. (C) Confocal images of FRAP of HUVECs expressing 
SDC4-eGFP or SDC4 Y180-A-eGFP at the time points indicated in the presence or absence of VEG FA 
stimulation. FRAP and image capture were performed using a Zeiss LSM 800 confocal laser scanning 
microscope with a 63x objective. (D) Quantification of fluorescence recovery of Sdc4-eGFP and (G) plots 
of the half-life of recovery for each of the treatments. n=3, **p<0.01, 
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SDC4 is required for efficient VE-Cadherin redistribution at EC junctions in response to VEGFA. (A) 
lmmunofluorescence staining for endogenous SDC4 (green) shows co-localization with VE-Cadherin (red) 
and VEGFR2 (purple) at EC junctions. Scale bar, 20 µm. (B) Confocal micrographs of HUVECs showing 
proximity ligation puncti on the cell surface (red dots) between SDC4 and VE-Cadherin (nuclei, blue; 
VE-Cadherin, green). An example of junctional punctum (yellow arrow) and a non-junctional punctum 
(white arrow) is shown on the right hand micrograph. Scale bar, 10 µm. (C) Quantification of 
SDC4NE-Cadherin PLA puncta on the cell surface over time after VEGFA stimulation (1 Ong/ml). (D) 
MLECs from WT and Sdc4-/- mice were washed with PBS and incubated with anti-VE-Cadherin antibody 
at 4 °C for 1 hour. Unbound antibody was washed away and cells stimulated with VEG FA (30 ng/ml) for 10 
min at 37 °C to promote VE-Cadherin internalization. Cells were then subjected to an acid wash to remove 
cell surface antibody. VE-Cadherin (red), DAPI (blue). Scale bar, 20 µm. (E) Images of MLECs treated with 
VEGFA and acid-washed were analyzed on lmaris software and VE-cadherin+ vesicles were counted and 
divided by the number of nuclei in the field of view. n=3. Images are representative of one experiment 
where 9 images per condition were analyzed (F) Evans blue was injected into the tail vein of WT and 
Sdc4-/- mice, followed by subcutaneous injections of PBS, VEG FA (100 ng) or Bradykinin (BK, 100 µg). 
Images show the local extravasation of the dye from underneath the skin 90 minutes post-injection, white 
circles indicate the approximate injection area. (G) Skin punches corresponding to the injection sites were 
collected and Evans blue extracted in formamide overnight. Permeability was quantified by measuring the 
optical density at 620 nm of the skin extracts and values were normalized on the basis of tissue weight. 
n=6-8 animals per condition. Data are mean± s.e.m. *P < 0.05; **P < 0.01; ****P<0.0001. Statistical 






B _ 100 * 
VEGFA VEGFA + soIS4 
Q) 90 (.) • --UT soIS4 (post-acid wash) (post-acid wash) Cl) 80 Q) u 70 
"in 
6 
Q) 60 > • "16 + 50 © C 4-~ ·c 40 i Q) ■ ..c 30 0 "O • ■ ■ D ctl 
~ u 20 • :Ii I w 10 
> • ■ 0 
VEGFA 
VEGFA + soIS4 
D E 20 *** ns -::i:: 
"O 3.0 
□ ur LL (!) * (9 N ~ 2.5 al VEGFA w Cl 15 
E 
0 > c-* ·- Cl • 0 2.0 - C :::i ·- • r--7 0 ,._ C ,._ ----
OiGi 
o.. 2 10 
~ 1.5 -.::I" Cl) :::i 
(f) 0 0 • ro ·- ,._ c, 1.0 
D 
0 t 0.. • Cl) 0 Cl) .E + <(- 5 0.5 
ro -::i:: 
~ 0.0 LL <( (9 
+ soIS4 + soIS2 w 0 > VEGFA VEGFA 
Lectin GS-II + soIS4 
PBS aflibercept soIS4 G ** ----..,. 
*** ~ 15 
>< • 
Cl) • 
~ 10 • • • • • s + ctl • Q) 5 • • • ,._ t ctl I C 0 "in 0 Q) 
_J PBS aflibercept soIS4 
The extracellular core protein of SDC4 (s0154) inhibits VEGFA induced VE Cadherin internalization 
in vitro and choroidal neovascularization in vivo. A) Confocal images of VE-Cadherin antibody 
'washout' experiments. WT MLECs were washed with PBS and incubated with anti-VE-Cadherin antibody 
at 4 °C for 1 hour. Unbound antibody was washed away and cells stimulated with VEG FA (30 ng/ml) for 10 
min with or without SolS4 (3.5 nM) at 37 °C to promote VE-Cadherin internalization followed by acid 
washing. VE-Cadherin (white). Scale bar, 20 µm. (B) Images of MLECs treated with VEGFA and 
acid-washed were analyzed on lmaris software and VE-cadherin+ vesicles were counted and divided by 
the number of nuclei in the field of view. 9 images per condition were analyzed. n=3 Scale bar, 20 µm. (C) 
HUVECs were scratched and incubated in serum-free media with or without VEGFA (20 ng/ml) and with or 
without SolS4 or solS2 (3.5 nM) for 16 hours. Migrated area was calculated by subtracting the final scratch 
area to the initial scratch area using lmageJ. n=3. (D) Micrographs of C57BL6 murine aortic rings 
embedded in Collagen I and cultured as explants in VEGFA-containing medium with or without solS4 (3.5 
nM) for 7 days. (E) Manual quantification of angiogenic sprouts. (n=4, 5-15 rings/condition). Scale bar, 10 µ 
m. (F) Fundus fluorescein angiograms of WT animals at day 7 post laser induced CNV. lntravitreal injection 
of 1 µI of either PBS, Aflibercept (10 µg) or solS4 (100 ng) were performed at day 0 directly after laser 
burns were applied. Scale bar, 2.4 mm. (G) The CNV lesion areas were quantified using lmageJ, each dot 
represents the average of 3 lesions per eye. n=?-9 animals per condition. Data are means and error bars 
indicate SEM in B, C and G and min and max values in E. *P < 0.05; **P < 0.01; ***P<0.001. 
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SUPPLEMENTAL MATERIAL AND METHODS 
Study design: The objective of animal studies described here was to evaluate the 
role of SDC4 in developmental angiogenesis, pathological neovascularization in the 
eye and in tumor models. Sample size was based on power calculations. In the laser 
induced CNV study, 7 represented the optimum number of animals needed to attain 
statistical significance of p<0.05 with a 90% probability given our pilot study values of 
7 ±2 for group 1 and 4 ±1.5 for group 2. N was increased to 9 per group given the 
incidence of post-laser hemorrhage. The end-point of the experiment was day 7. 
Lesions that showed hemorrhage or two lesions fused together were excluded from 
analysis. For OIR experiments, 17 represented the minimum number of animals 
needed to attain statistical significance of p<0.05 with an 80% probability given our 
pilot study values of 4 ± 2 for group 1 and 2.5 ± 1 for group 2. N was increased to 21 
per group. Three separate OIR experiments were performed and the end-point of the 
experiment was day 17. In developmental retinal angiogenesis study, 8 represented 
the optimum number of animals needed to attain statistical significance of p<0.05 
with a 90% probability given our pilot study values of 30±4 for group 1 and 25±2 for 
group 2. N was increased to 9 per group. End-point of the experiment was day 6. 
Investigators were blinded during all phases of the experiments and genotypes or 
treatments groups only revealed after analysis.  
List of reagents: The following dyes and reagents were used in this work; lectin GS-
II Alexa594 (Thermo Fisher Cat#L21416), DAPI (Sigma-Aldrich, Cat#D9542), Draq5 
(Biostatus limited Cat#DR05500), recombinant mouse VEGFA 164 (R&D Systems 
Cat#493-MV-025m), Bradykinin (Sigma Cat#B3259), recombinant syndecan-4 (R&D 
Systems Cat# 6267-SD-050) and recombinant syndecan-2 (R&D Systems 
Cat#6585-SD-050), proteome profiler human phospho-kinase array kit (R&D 
Systems Cat#ARY003B), Halt™ Protease and Phosphatase Inhibitor Single-Use 
Cocktail (100X) (Thermofisher Cat#78440), EZ-Link™ Sulfo-NHS-Biotin, No-
Weigh™ Format (Thermofisher Cat#A39256), Pierce™ NeutrAvidin™ Agarose 
(Thermofisher Cat#29200). 
Immunohistochemical (IHC) staining of papillomas: Samples of back skin from 
sacrificed, shaved control mice or mice at 43 hours or week 17 of the tumor induction 
experiment were collected and fixed with 4% paraformaldehyde and embedded in 
paraffin according to standard protocols. Hematoxylin/eosin staining and DAB 
immune-histochemical staining (IHC) was performed on 6 µm thick paraffin sections 
as previously described in33. Rat anti-CD31 (BD Pharmingen, Oxford, UK) primary 
antibody was used for IHC. The blocking reagents used for IHC were S2O23 REAL 
and S0809 Antibody Diluent (Dako).  The horseradish peroxidase (HRP) conjugated 
secondary antibody used was 414311F anti-rat Histofine (Nichirei Bio, Tokyo, Japan) 
and peroxidase reactive chromogens used was K3465 DAB (DAKO).  
Quantitative analysis of immunostaining and histochemical staining: All slides 
were scanned using the Aperio ScanScope® CS and XT systems (Aperio 
Technologies Inc., California, USA) as previously described33. Slides were viewed 
and analyzed remotely using desktop personal computers employing the web-based 
ImageScope™ viewer. The Spectrum digital pathology system analysis algorithm 
package and Image Scope analysis software (version 9; Aperio Technologies Inc.) 
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were applied to quantify immune-histochemical signal. These algorithms calculate 
the area of positive staining, the average positive intensity (optical density), as well 
as the percentage of weak (1+), medium (2+), and strong (3+) positive staining. The 
quantified CD31 expression was performed according to the protocols used to 
establish these algorithms for each respective staining33. Blood vessel diameter was 
determined from CD31-stained tissue sections by drawing a straight line from the 
outer edges of CD31-staining on all blood vessels with distinguishable lumen. 
qPCR: RNA was purified using the Qiagen RNeasy Microkit as described by the 
manufacturers, cDNA was synthesized from 10 ng total RNA using the iScript cDNA 
synthesis kit (Biorad), quantitative real time PCR was performed on an ABI7900HT 
(Applied Biosystems) real time PCR machine  using the iQ Sybr green supermix 
(Biorad). Sequences of primers used in this are as follows: Mouse syndecan-1 
forward 5’-GGT GGA CGA AGG AGC CAC A-3’, mouse syndecan-1 reverse 5’-CTC 
CGG CAA TGA CAC CTC C-3’, mouse syndecan-2 forward 5’-GAG GCA GAA GAG 
ATG CTG G-3’, mouse syndecan-2 reverse 5’-CAT CAA TGA CGG CTG CTA G-3’, 
mouse syndecan-3 forward 5’-GCC CTG GCC TCC ACG AC-3’, mouse syndecan-3 
reverse 5’-CAC GAT CAC GGC TAC GAG C-3’, mouse syndecan-4 forward 5’-CAC 
GAT CAG AGC TGC CAA G-3’, mouse syndecan-4 reverse 5’GGA TGA CAT GTC 
CAA CAA AGT-3’, mouse GAPDH forward 5’-TCG TGG ATC TGA CGT GCC GCC 
TG-3’, mouse GAPDH reverse 5’-CAC CAC CCT GTT GCT GTA GCC GTA T-3’. 
Human samples: Pre-retinal neovascular membranes were obtained from type I 
diabetic patients who were undergoing pars plana vitrectomy for the treatment of 
proliferative diabetic retinopathy. These patients had already developed tractional 
retinal detachment due to fibrosis of neovascular membranes. Thus, the samples 
represent the end stage disease, where substantial amount of fibrosis was 
associated with neovessels, but still contained regions with active pathologic 
angiogenesis. All patients were Caucasians, males and females, aged between 27–
56 years, and mean duration of diabetes was 24 years (range, 21–28 years). The 
protocol for collecting human tissue samples was approved by the Institutional 
Review Boards of the Pirkanmaa Hospital District. The study was conducted in 
accordance with the Declaration of Helsinki. All patients gave written informed 
consent. During vitrectomy, the fibrovascular membranes were isolated, grasped 
with vitreous forceps, and pulled out through a sclerotomy. The sample was 
immediately fixed with 4 % formaldehyde for 3 h, transferred to 70 % ethanol, 
embedded in paraffin, and processed for immunohistochemistry. Adjacent 5 µm 
sections were stained for anti-CD31, anti-VEGFR2 and anti-SDC4 KY/8.2 followed 
by horseradish peroxidase (HRP) conjugated secondary antibodies. The slides were 
imaged via Olympus light microscope and Cell Sens Dimensions software. 
Quantification was done using IHC Profiler plugin in ImageJ 1.44p software (National 
Institutes of Health, Bethesda, MD).  The same region of interest was selected from 
all stained sections (2-3 sections per sample) and the area (%) of total positive 
staining was quantified. To analyze the correlation between SDC4, VEGFR2 and 
CD31 positive area in each ROI, a multiple linear regression analysis was done in 
IBM SPSS Statistics.  
Immunohistochemistry (IHC) and Isolectin GS-IB4 Staining of mouse retinas: 
For the analysis of murine retinal vasculature, eyes were enucleated, fixed with 4% 
paraformaldehyde (PFA), and retinas dissected. Flat-mount retinas were blocked in 
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20% normal goat and 20% fetal bovine serums for 2 hours, incubated overnight 
Isolectin (Isolectin GS-IB4, 1:200; Invitrogen, Carlsbad, CA, USA) and with anti-VE-
cadherin antibody, followed by Alexa Fluor-conjugated secondary antibody. The 
samples were mounted with Vectashield mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA) and images were captred by confocal microscopy. 
(Carl Zeiss LSM 700).  
 
Matrigel plug assay: Matrigel (400 µl, BD Biosciences) was thawed on ice and 
mixed with 100 μl PBS containing growth factors 100 ng/ml VEGFA and 20 U/ml of 
Heparin (Sigma) and injected subcutaneously into the flank of male anesthetized 6 
week old mice roughly between the rib cage and the posterior leg. After 5 days, mice 
were sacrificed by cervical dislocation and plugs recovered after dissection. Plugs 
were imaged using a conventional digital camera, weighed on a precision balance 
and incubated overnight at 4 °C with 500 μl of dH2O. The amount of hemoglobin 
released from the plugs was measured using the Drabkin reagent kit (Sigma) as 
described by the manufacturer. Absorbance at 540 nm was read using a 
spectrophotometer and results quantified using a standard curve of known 
concentrations of hemoglobin and data was expressed as the concentration of 
hemoglobin per gram of plug (HG mg/ml/g). 
Choroid and aortic sprouting assay: Aortic rings were prepared from 6-8 week old 
male mice. Briefly, aortas were dissected, washed in PBS and fat and side branches 
were removed prior to slicing into rings (~1mm diameter) and these were incubated 
o/n in serum-free OptiMEM (containing Penicillin-Streptomycin) at 37 °C. Choroid 
explants were prepared from eyes, as follows; eyes were punctured with scissors, an 
incision was made 1 mm below the iris and the iris/cornea/lens/retina were removed. 
The choroid was cut into approximately 1 mm2 pieces (~ 4 from central, 6 from 
periphery) and incubated o/n in OptiMEM, as above. Explants were embedded in 
150 µl/well of a type I collagen matrix (1 mg/ml) in E4 media (Invitrogen) in a 48-well 
plate (Corning). Plates were incubated at 37 °C for 30 min to allow the collagen to 
solidify, after which time wells were supplemented with 200 µl OptiMEM with 1 % 
FBS and VEGFA (30 ng/ml) and incubated at 37 °C, 10 % CO2. Media was 
replenished every third day and angiogenic sprouts from aortic rings or choroid 
explants were counted after 1 week and results were expressed as the number of 
sprouts per ring or explant. 
Primary mouse lung endothelial cell (MLEC) isolation and HUVEC culture: Cells 
were isolated and cultured from male WT and Sdc4-/- animals as described 29. 
HUVECs were obtained from Promocell and were grown and maintained according 
to supplier’s instructions in ECGM2 medium C-22111. RAW 246.7 macrophages 
were obtained from HPA culture laboratories (Public Health Laboratories, UK) and 
grown in DMEM supplemented with 10% FCS. 
Migration assay: Cells were cultured in 6- or 12-well plates until confluent and 
serum starved for 3 hours. One longitudinal scratch was introduced to the monolayer 
with a sterile pipette tip, cells were then washed to remove debris and incubated in 
fresh medium. Regions of interests in the scratch area were recorded using Cell^M 
software (Olympus) and micrographs of ROIs taken every 30 min for 16 hours with 
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an Olympus IX81 inverted microscope. The initial and final gap was measured using 
ImageJ software (NIH). 
Lentiviral constructs: cDNA encoding the full-length sequence of murine SDC4 
(Sdc4-eGFP) was synthesized to include either the complete coding sequence of 
eGFP or the HA epitope inserted between I32 and D33 of the extracellular domain. 
These provided the template to perform site directed mutagenesis to generate the 
various mutant forms of SDC4 used in this study. The cDNAs were ligated into the 
BamHI and XhoI sites of the lentiviral vector plentiSFFV-MCS using conventional 
procedures. Lentiviruses were packaged in HEK 293T cells under the control of the 
GagPol promoter using the VSVG envelope protein. HUVECs and MLECS were 
transfected by overnight incubation with viral preparations. 
Immunoprecipitation and western blot. Confluent EC monolayers were lysed in 
TBS containing 1% v/v triton x100 and HALT phosphatase inhibitors (Thermo 
Fisher). Immuno-precipitation of HA tagged SD4 proteins was performed using anti-
HA Agarose beads (Pierce).  Beads and lysates were incubated o/n at 4oC and 
beads harvested by centrifugation. Beads were washed 3x with TBS prior to 
incubation in Laemmli buffer and analysis by western blot. Chemiluminescent 
detection of proteins was performed using an Azure c600 imaging system using the 
manufacturer’s reagents. 
Biotinylation: Primary MLECs (WT and Sdc4-/-) were starved for 1 hour in ECGM2 
(without supplement or FBS and VEGFA was added (50 ng/ml for 15’). Cells were 
washed on ice twice with PBS (with Calcium and Magnesium), sulfo-NHS-biotin was 
dissolved in PBS at a concentration of 0.5 mg/ml and incubated with the cells for 20’ 
on a shaker on ice. Cell were washed twice in PBS and blocked with complete 
ECGM2 for 20’ on ice, after which lysates were made (lysis buffer composed of TBS, 
EDTA 10 mM, 1% tryton X100, phosphatase/protease inhibitor cocktail). A small 
volume was kept to represent whole lysates, while remaining sample was incubated 
with neutravidin-agarose for 2 hours at 4°C, centrifuged, washed 3 times with lysis 
buffer and resuspended in Laemmli buffer for western-blotting analysis. 
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Major Resources Table 
In order to allow validation and replication of experiments, all essential research materials listed in the 
Methods should be included in the Major Resources Table below. Authors are encouraged to use public 
repositories for protocols, data, code, and other materials and provide persistent identifiers and/or links to 
repositories when available. Authors may add or delete rows as needed. 
Animals (in vivo studies) 
Species Vendor or Source Background Strain Sex Persistent ID / URL 
Mouse Charles River C57BL/6J m/f  
Mouse  CARD, Kunamoto 
university, Japan 
C57BL/6J Sdc4-/- m/f  




Target antigen Vendor or 
Source 






Persistent ID / 
URL 
VEGFR2 Santa cruz 6251 1 µg/ml   
VEGFR2 Cell signaling 2479 1:1000    
Syndecan-4 Abcam 24511 5 µg/ml   
Syndecan-4 eBiovision 3644 5 µg/ml 4AIIL36440  
CD31 BD 
Pharmingen 
550274 1.5 µg/ml   
VE-Cadherin Abcam 33168 1 µg/ml   
VE-Cadherin eBioscience 14-1441-
82 
5 µg/ml   
VE-Cadherin Santa cruz 9989 0.8 µg/ml E1018  
Alpha-SMA Sigma A2547 1 µg/ml   
VEGFR2pY1175 Cell signaling 9698 1:1000   
Beta-tubulin Sigma T4026 0.1 µg/ml 043M4785  
VEGFR2-FITC BD 
Pharmingen 
560680 2.5 µg/ml 01750  
IgG2a,k-FITC BD 
Pharmingen 
553929 2.5 µg/ml   
Syndecan-4-PE BD 
Pharmingen 
550352 2.5 µg/ml 6204630  
IgG2a,k-PE BD 
Pharmingen 
553930 2.5 µg/ml   
Podocalyxin R&D systems AF1556 10 µg/ml   
 
 






for HA tag 
inserted 
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that S44,62,64 is 
mutated to 
Alanine. 





























cDNA for eGFP 
inserted 
between I31 and 
D32. 







mutated at Y180 
to A. 








mutated at Y180 
to F. 







Name Vendor or Source Sex (F, M, or 
unknown) 
Persistent ID / URL 
Human umbilical vein 
endothelial cells 
(HUVECs) 
Promocell Mix donors pooled  
RAW 246.7 
macrophages 
HPA male  
    
 
